CXCR4 ANTAGONIST AS AN ADJUVANT IN IMMUNOTHERAPY OF EPITHELIAL OVARIAN CANCER

$771,750FY2016Department of the ArmyDOD

Health Research, Inc., Rockville MD

Investigators

View source on USAspending →